US3592899A - Compositions containing 4-(isoxazol-3 or 5-yl)-pyridinium salts and method of lowering blood sugar levels - Google Patents

Compositions containing 4-(isoxazol-3 or 5-yl)-pyridinium salts and method of lowering blood sugar levels Download PDF

Info

Publication number
US3592899A
US3592899A US875528A US3592899DA US3592899A US 3592899 A US3592899 A US 3592899A US 875528 A US875528 A US 875528A US 3592899D A US3592899D A US 3592899DA US 3592899 A US3592899 A US 3592899A
Authority
US
United States
Prior art keywords
methyl
isoxazolyl
chloride
pyridinium
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US875528A
Inventor
Victor John Bauer
Sidney Robert Safir
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Application granted granted Critical
Publication of US3592899A publication Critical patent/US3592899A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

  • This invention relates to new compositions of matter. More particularly, it relates to quaternary isoxazolylpyridinium salts and quaternary isothiazolylpyridinium salts as the active components of said compositions and method of use thereof.
  • R is selected from the group consisting of hydrogen, lower alkyl, and trihalo(lower)alkyl
  • R is selected from the group consisting of hydrogen and lower alkyl
  • R is selected from the group consisting of lower alkyl, lower alkenyl, cyc1oalkyl(lower)alkyl and lower alkoxy- (lower)alkyl
  • Z is a trivalent radical selected from the group consisting of represents one double bond
  • X is a pharmaceutically acceptable anion.
  • the anion may be, for example, chloride, bromide, iodide, and the like.
  • the dotted line represents one double bond, the position of which is dependent upon the definition of Z.
  • lower alkyl is intended to include those having 1 to 4 carbon atoms.
  • halogen includes chlorine, bromine, fluorine, iodine.
  • Lower alkenyl includes those having 1 to 4 carbon atoms.
  • the active components are crystalline solids, soluble in water.
  • the active components of the present invention may be prepared by any of several general reaction sequences.
  • a l (4 pyridyl) 1,3 alkylidone or a l-(4- pyridyl)-1,3-alkylidione salt is reacted with a hydroxylamine salt, such as the hydrochloride, in a polar solvent, such as water or alcohol, at a temperature of 25 to C. for a time of one minute to twenty-four hours with or without the addition of a base, such as sodium carbonate, to provide either a 4 isoxazolylpyridine or a 1-(4- pyridyl)-1,3-alkyldione oxime.
  • an oxime When an oxime is formed, it is converted to a 4-isoxazolylpyridine by treatment with a dehydrating agent, such as acetyl chloride or concentrated sulfuric acid, at a temperature of 0 to 100 C. for a time of one minute to twenty-four hours.
  • a dehydrating agent such as acetyl chloride or concentrated sulfuric acid
  • the 4-isoxazolylpyridine is quaternized to a 4-isoxazolylpyridinium salt, a compound of this invention, by reaction with a lower alkyl, lower .alkenyl, cycloalkylflower alkyl, or lower alkoxy(lower)alkyl halide at a temperature of 0 to 150 C.
  • a 1-(4 pyridyl)-1,3-alkyldione is reacted with a lower alkyl halide at a temperature of 0 to 150 C. for a time of one minute to twenty-four hours with or without a solvent, such as alcohol, in an open vessel or a sealed bomb to form a quaternary salt, which is then cyclized with a hydroxylamine salt, such as the hydrochloride, in a polar solvent, such as water or alcohol, at a temperature of 25 to C. for a time of one minute to twenty-four hours to a separable mixture of 4-(S-isoxazolyhpyridinium salt and a 4-(3-isoxazolyl) pyridinium salt.
  • an acetylene is allowed to react with a pyridinenitrile oxide, formed in situ from an isonicotinohydroxamyl chloride and triethylamine, to provide a 4- isoxazolylpyridine, which is quaternized as described above.
  • an isoxazolylpyridine is hydrogenated to provide an aminopyridyl-butenone, which is fused with phosphorus pentasulfide to provide an isothiazolylpyridine.
  • Reaction of the isothiazolylpyridine with an alkyl halide provides a quaternary isothiazolylpyridinium salt, an active component of this invention.
  • the active components of the present invention show hypoglycemic activity in warm-blooded animals which indicates they are useful as medicaments in the lowering of blood sugar levels.
  • mice used in these studies are MF-l (Manor Farms, 18-25 grams).
  • the active components of this invention are administered by gavage as saline solutions. Control animals receive an equivalent volume of vehicle. Food is withheld from animals after dosing. Blood gulcose is determined 2 to 6 hours after dosing by the method of Hoffman [1. Biol. Chem, 120, 51 (1937)] as adapted to the Technicon Auto Analyzer and is expressed as percent change from saline controls. Blood samples are obtained from the tail veins of mice. The testing data is summarized in Table I.
  • compositions of the present invention are useful in the lowering of blood glucose in normal and hyperglycemic warm-blooded animals at a dose of from 1 mg. to 500 mg. per kilogram of body weight.
  • the active components of this invention can be used in compositions such as tablets; the principal active ingredient is mixed with conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate, gums, and fractionally similar materials as pharmaceutical diluents or carriers.
  • the tablets or pills of the novel compositions can be laminated or otherwise compounded to provide a dosage form affording the advantage of prolonged or delayed action or predetermined successive action of the enclosed medication.
  • the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former.
  • the two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release.
  • enteric layers or coatings such materials including a number of polymeric acids or mixtures of polymeric acids with such materials as shellac, shellac and cetyl alcohol, cellulose acetate and the like.
  • enteric coating comprises a styrene maleic acid copolymer together with known materials contributing to the enteric properties of the coating.
  • liquid forms in which the novel compositions of the present invention may be incorporated for administration include suitably flavored emulsions with edible oils, such as, cottonseed oil, sesame oil, coconut oil, peanut oii, and the like, as well as elixirs and similar pharmaceutical vehicles.
  • edible oils such as, cottonseed oil, sesame oil, coconut oil, peanut oii, and the like, as well as elixirs and similar pharmaceutical vehicles.
  • Sterile suspensions or solutions are required for parenteral use.
  • Isotonic preparations containing suitable preservatives are also highly desirable for injection use.
  • dosage form as described herein refers to physically discrete units suitable as unitary dosage for warm-blooded animal subjects, each unit containing a predetermined quantity of active component calculated to produce the desired therapeutic effect in association with the required pharmaceutical diluent, carrier or vehicle.
  • the specification for the novel dosage forms of this invention are dictated by and are directly dependent on (a) the unique characteristics of the active component and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such an active component for therapeutic use in warmblooded animals as disclosed in this specification, these being features of the present invention.
  • suitable oral dosage forms in accord with this invention are tablets, capsules, pills, powder packets, granules, wafers, cachets, teaspoonfuls, dropperfuls, ampules, vials, segregated multiples of any of the foregoing and other forms as herein described.
  • EEQP 264 me EXAMPLE III
  • 4- 5-isoxazolyl)pyridine To a solution of 103 g. (0.6 mole) of 1-(4-pyridyl)-1,3- propanedione sodium salt in 500 ml. of water is added 44 g. of hydroxylamine hydrochloride. After several minutes, the solution is adjusted to pH 8 with sodium carbonate, and the solid which separates is collected. Recrystallization from methanol gives 52 g. of colorless crystals, melting point 152-153 C., dec., of l-(4-pyridyl)-1,3-propanedione 3-oxime.
  • This solid is a 1:1 mixture of 1-methyl-4-(3- methyl-S-isoxazolyl)pyridinium chloride and l-methyl-4- 1 l (i-methyl-ll-isoxazolyl)pyridinium chloride.
  • the mixture is separated into two components by partition chromatography.
  • the first eluted material is recrystallized from acetonitrile to provide colorless crystals, melting point 22l-222 C., dec., of 1-methyl-4-(5-methyl-3isoxazolyl) pyridinium chloride.
  • Each tablet contains mg. of active component.
  • a method of lowering blood sugar levels in warmblooded animals which comprises administering to said animals a blood sugar lowering amount of a quaternary isoxazolylpyridinium salt of the formula:
  • R is selected from the group consisting of hydrogen, lower alkyl, and trifiuoromethyl
  • R is selected from the group consisting of hydrogen and lower alkyl
  • R is selected from the group consisting of lower alkyl, lower alkenyl, cyclopropyl(lower)alkyl and lower alkoxyflower)alkyl
  • Z is a trivalent radical selected from the group consisting of and i t; :N O/
  • X is a monovalent pharmaceutically acceptable anion and a pharmaceutical carrier.
  • compositions for lowering blood sugar levels in warmblood animals which comprises a pharmaceutically acceptable carrier and from 1 mg. to 500 mg. per kilograms of warm-blooded animal body weight of a quaternary isoxazolylpyridinium salt of the formula:
  • X is a monovalent pharmaceutically acceptable anion
  • composition according to claim 8 wherein the quaternary isoxazolylpyridinium salt is l-methyl-4-(3- methyl-S-isoxazolyl)pyridinium chloride.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)

Abstract

THIS APPLICATION DESCRIBES COMPOSITIONS CONTAINING QUATERNARY ISOXAZOLYLPYRIDINIUM SALTS AND QUATERNARY ISOTHIAZOLYLPYRIDINIUM SALTS AND ALSO THE METHOD OF USE OF THE ISOXAZOLYLPYRIDINIUM SALTS AND ISOTHIAZOLYLPYRIDINIUM SALTS. THESE COMPOSITIONS ARE USEFUL IN WARM-BLOODED ANIMALS FOR THEIR HYPOGLYCEMIC ACTIVITY.

Description

United States Patent ce US. Cl. 424-263 9 Claims ABSTRACT OF THE DISCLOSURE This application describes compositions containing quaternary isoxazolylpyridinium salts and quaternary isothiazolylpyridinium salts and also the method of use of the isoxazolylpyridinium salts and isothiazolylpyridinium salts. These compositions are useful in warm-blooded animals for their hypoglycemic activity.
This application is a continuation-in-part of our application Ser. No. 662,281, filed Aug. 22, 1967, now US. Pat. 3,511,848. which in turn is a continuation-in-part of our application Ser. No. 535,714, filed Mar. 21, 1966, now abandoned.
SUMMARY OF THE INVENTION This invention relates to new compositions of matter. More particularly, it relates to quaternary isoxazolylpyridinium salts and quaternary isothiazolylpyridinium salts as the active components of said compositions and method of use thereof.
The active components of the new compositions of the present invention may be illustrated by the following forwhere R is selected from the group consisting of hydrogen, lower alkyl, and trihalo(lower)alkyl, R is selected from the group consisting of hydrogen and lower alkyl, R is selected from the group consisting of lower alkyl, lower alkenyl, cyc1oalkyl(lower)alkyl and lower alkoxy- (lower)alkyl, Z is a trivalent radical selected from the group consisting of represents one double bond and X is a pharmaceutically acceptable anion. The anion may be, for example, chloride, bromide, iodide, and the like. The dotted line represents one double bond, the position of which is dependent upon the definition of Z. When Z is the double bond is adjacent to R and when Z has the other meanings, the double bond is adjacent to the pyridinium ring. The term lower alkyl is intended to include those having 1 to 4 carbon atoms. The term halogen includes chlorine, bromine, fluorine, iodine. Lower alkenyl includes those having 1 to 4 carbon atoms.
3,592,899 Patented July 13, 1971 In general, the active components are crystalline solids, soluble in water.
The active components of the present invention may be prepared by any of several general reaction sequences. Thus, a l (4 pyridyl) 1,3 alkylidone or a l-(4- pyridyl)-1,3-alkylidione salt is reacted with a hydroxylamine salt, such as the hydrochloride, in a polar solvent, such as water or alcohol, at a temperature of 25 to C. for a time of one minute to twenty-four hours with or without the addition of a base, such as sodium carbonate, to provide either a 4 isoxazolylpyridine or a 1-(4- pyridyl)-1,3-alkyldione oxime. When an oxime is formed, it is converted to a 4-isoxazolylpyridine by treatment with a dehydrating agent, such as acetyl chloride or concentrated sulfuric acid, at a temperature of 0 to 100 C. for a time of one minute to twenty-four hours. The 4-isoxazolylpyridine is quaternized to a 4-isoxazolylpyridinium salt, a compound of this invention, by reaction with a lower alkyl, lower .alkenyl, cycloalkylflower alkyl, or lower alkoxy(lower)alkyl halide at a temperature of 0 to 150 C. with or without a solvent, such as alcohol, for a time of one minute to twenty-four hours in an open vessel or a sealed bomb. Alternatively, a 1-(4 pyridyl)-1,3-alkyldione is reacted with a lower alkyl halide at a temperature of 0 to 150 C. for a time of one minute to twenty-four hours with or without a solvent, such as alcohol, in an open vessel or a sealed bomb to form a quaternary salt, which is then cyclized with a hydroxylamine salt, such as the hydrochloride, in a polar solvent, such as water or alcohol, at a temperature of 25 to C. for a time of one minute to twenty-four hours to a separable mixture of 4-(S-isoxazolyhpyridinium salt and a 4-(3-isoxazolyl) pyridinium salt.
Alternatively, an acetylene is allowed to react with a pyridinenitrile oxide, formed in situ from an isonicotinohydroxamyl chloride and triethylamine, to provide a 4- isoxazolylpyridine, which is quaternized as described above. For the synthesis of isothiazolylpyridinium salts, an isoxazolylpyridine is hydrogenated to provide an aminopyridyl-butenone, which is fused with phosphorus pentasulfide to provide an isothiazolylpyridine. Reaction of the isothiazolylpyridine with an alkyl halide provides a quaternary isothiazolylpyridinium salt, an active component of this invention.
The intermediate isoxazolylpyridines and isothiazolylpyridines before quaternization may be illustrated by the following formula:
METHOD A O O a O acorn-ll- \N or nil-enh- NOH O OH METHOD 0 NOH wherein R, R R and X are as defined above.
1-methyl-4-(3-ethyl-5-isoxazoly1)pyridinium chloride,
1-allyl-4- 3-methyl-5-isoxazolyl pyridinium chloride,
1 -methyl-4-( 3-methyl-5-isoxazoly1)pyridinum cholired,
1-methy1-4- 5-methyl-3-isoxazolyl pyridinium chloride,
1-allyl-4-(S-ethyl-3isoxazolyl) pyn'dinum chloride,
1-methyl-4-( 3-propyl-5-isoxazolyl) pyridinum chloride,
1-methyl-4- 3-trifluoromethyl-5-is0xazolyl pyridinium chloride,
1- Z-methoxyethyl -4- (3-methyl-5-isoxazolyl) pyridinium chloride,
1-cyclopropylmethyl-4- 3-methyl-S-isoxazolyl pyridinium chloride,
1,3-dimethyl-4- (3-methyl-5-isoxazolyl) pyridinium chloride,
l-methyl-4-(3-methyl-5-isothiazolyl) pyridinium iodide,
l-methyl4- (5-rnethyl-3 -isothiazolyl pyridinium chloride, and the like.
The active components of the present invention show hypoglycemic activity in warm-blooded animals which indicates they are useful as medicaments in the lowering of blood sugar levels. When the active components are administered orally to normal mice, a reduction of blood sugar levels is observed. Mice used in these studies are MF-l (Manor Farms, 18-25 grams). The active components of this invention are administered by gavage as saline solutions. Control animals receive an equivalent volume of vehicle. Food is withheld from animals after dosing. Blood gulcose is determined 2 to 6 hours after dosing by the method of Hoffman [1. Biol. Chem, 120, 51 (1937)] as adapted to the Technicon Auto Analyzer and is expressed as percent change from saline controls. Blood samples are obtained from the tail veins of mice. The testing data is summarized in Table I.
TABLE I Percent decrease in blood glucose Hoflzs at dosage of-- a Compound dosing 125 mg./kg. 250 mg./irg. 500 mg./kg.
l-methyl-4-(3-methyl-5-isoxazolyl)pyridinium chloride 4 36*5 40 8 69* 5 1-1nethyl-4(3-eth l-o-isoxazolyl)pyridinium chloride. 4 24* 3 44=+=7 63* 7 1-a1ly1-4-(3-methy -5-isoxazolyl) pyridiuium chloride 4 1l= =9 9:8 3!): i4 2 24:4 4:: 6 10: 6 l-methyll-(5is0xazolyl)pyridinium chloride =1 24* 2 4= 8 2 6 34* 3 0:7 12*6 2 12: 2 27 #7 4 1,3-dimethyl-4-(Ii-methyl-Msoxnzolyl)pyridinlum chloride 4 14* 10 36* 13 76* 8 [i 11:11 42*13 76:3 2 18* 7 26* 3 30* 7 I-(Z-methoxyethyl) --i(3-methy1-5-isoxezolyDpyridinium chloride 4 4* 7 15* 6 31 13 6 7* Si 9* 7 22 l l I-methyl-4-(fi-trifluoromethyl-li-isoxazolyl)pyridinium ch1oridc g 3 :3 l-rnethyli-(frmethyl-3-isoxazolyl) pyridinium chloride {a l-oyelopropylmethyl-4-(3-methyl-5-isoxazolyl)pyridinium bromide {Z H 2 3:3 gig l-ethyl-i(3-n1ethy1-5-isoxaz olyl) pyridiniurn iodide i I-ethyM-(Sethyl-fiisoxazolyl)'pyridinium iodide 32:3 ropyi-4-(3-methyl-5-lsoxazolyl) pyridinium bromide -methyl4-(3-methyl-5isothiazolyl) pyridinium iodide 5 1 13= =3 3 35*) 4 :9 1-111 eth l+(fi-methyl'sisothiazolyl) pyridinium iodide 3 5 62* 12 93*1 1 Values are means standard errors of 4 to 8 mice per dose and are expressed as percent decrease from predose values.
in Table II. 40
TABLE II [Oral hypoglycemic activity of l-methyl l-(3-methyl-5-isoxaaolvl) pyridinium chloride in cookerels, guinea pigs and alloxanized m1ce] Time Percent r after reduction 40 Dose, dosing, in blood Species and treatment mmol/kg. hrs. glucose Cockerels drug (10) Drug (27) Cockerels and guinea pigs Were lasted 24 hours before dosing. Food was withheld from all animals after dosings.
Values are means =1: SE. of number of animals indicated in parentheses and are expressed as percent reduction from predose levels or from saline control in the ease of cockerals (blood glucose of 10 saline control cockerels was 143:1;5 mg. percent).
' Significantly different from control.
These results show that the compositions of the present invention are useful in the lowering of blood glucose in normal and hyperglycemic warm-blooded animals at a dose of from 1 mg. to 500 mg. per kilogram of body weight.
The active components of this invention can be used in compositions such as tablets; the principal active ingredient is mixed with conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate, gums, and fractionally similar materials as pharmaceutical diluents or carriers. The tablets or pills of the novel compositions can be laminated or otherwise compounded to provide a dosage form affording the advantage of prolonged or delayed action or predetermined successive action of the enclosed medication. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids or mixtures of polymeric acids with such materials as shellac, shellac and cetyl alcohol, cellulose acetate and the like. A particularly advantageous enteric coating comprises a styrene maleic acid copolymer together with known materials contributing to the enteric properties of the coating.
The liquid forms in which the novel compositions of the present invention may be incorporated for administration include suitably flavored emulsions with edible oils, such as, cottonseed oil, sesame oil, coconut oil, peanut oii, and the like, as well as elixirs and similar pharmaceutical vehicles. Sterile suspensions or solutions are required for parenteral use. Isotonic preparations containing suitable preservatives are also highly desirable for injection use.
The term dosage form as described herein refers to physically discrete units suitable as unitary dosage for warm-blooded animal subjects, each unit containing a predetermined quantity of active component calculated to produce the desired therapeutic effect in association with the required pharmaceutical diluent, carrier or vehicle. The specification for the novel dosage forms of this invention are dictated by and are directly dependent on (a) the unique characteristics of the active component and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such an active component for therapeutic use in warmblooded animals as disclosed in this specification, these being features of the present invention. Examples of suitable oral dosage forms in accord with this invention are tablets, capsules, pills, powder packets, granules, wafers, cachets, teaspoonfuls, dropperfuls, ampules, vials, segregated multiples of any of the foregoing and other forms as herein described.
DETAILED DESCRIPTION The preparation of the active components of this invention along with compositions containing the same will be described in greater detail in the following examples.
7 EXAMPLE I Preparation of 4-(3-methyl-5-isoxazolyl) pyridine A solution of 22 g. (0.13 mole) of 4-acetoacetylpyri dine, 14 g. of hydroxylamine hydrochloride, 14 g. of sodium carbonate, 150 ml. of water, and 100 ml. of ethanol is heated under reflux for 12 hours. Then, 100 ml. of solvent is allowed to distill from the mixture, which is then extracted with benzene. The benzene solution is concentrated under reduced pressure to a colorless solid. Recrystallization from cyclohexane provides 14 g. (66%) of colorless crystals, melting point 62-65 C.,
CH 011 x 263 m.
EXAMPLE II Preparation of 4-(3-ethyl-5-isoxazolyl)pyridine A mixture of 40.5 g. (0.23 mole) of 1-(4-pyridyl)-1,3- pentanedione, 17.4 g. of hydroxylamine hydrochloride, 24.4 g. of sodium carbonate, 200 ml. of water, and 100 ml. of ethanol is heated under reflux for 18 hours. Then, 100 ml. of solvent is distilled, and the mixture is extracted with benzene. Concentration of the benzene solution leaves a red liquid which is crystallized from hexane to provide colorless crystals, melting point 48-49 C.,
EEQP 264 me EXAMPLE III Preparation of 4- 5-isoxazolyl)pyridine To a solution of 103 g. (0.6 mole) of 1-(4-pyridyl)-1,3- propanedione sodium salt in 500 ml. of water is added 44 g. of hydroxylamine hydrochloride. After several minutes, the solution is adjusted to pH 8 with sodium carbonate, and the solid which separates is collected. Recrystallization from methanol gives 52 g. of colorless crystals, melting point 152-153 C., dec., of l-(4-pyridyl)-1,3-propanedione 3-oxime.
A mixture of 38 g. (0.22 mole) of 1-(4-pyridyl)-1,3- propanedione 3-oxime and 150 ml. of acetyl chloride is heated under reflux for 2 hours. The excess acetyl chloride is distilled, and the residue is taken up in water and made basic with sodium hydroxide. The mixture is extracted with ether. Concentration of the ether solution leaves a yellow solid, which is recrystallized from ether to give 11 g. of colorless crystals, melting point 101- 102 C.
EXAMPLE IV Preparation of 4 (5 trifluoromethyl 3 isoxazolyl) pyridine A solution of 2.2 g. (0.01 mole) of 1-(4-pyridyl)-4,4,4- trifiuoro-1,3-butanedione, 0.7 g. of hydroxylamine hydrochloride, 20 ml. of ethanol, 5 ml. of water and 0.7 g. of sodium carbonate is heated under reflux for 12 hours, concentrated to a volume of 5 ml., and diluted with water. The solid which separates is recrystallized from isopropyl alcohol-water to provide 1.85 g. of colorless prisms, melting point 187 C., of 1 (4-pyridyl)-4,4,4,-trifluoro-1,3- butane-dione 1-oxime.
To 25 ml. of concentrated sulfuric acid is added during 15 minutes with stirring 10.0 g. of 1-(4-pyridyl)-4,4,4-trifiuoromethyl-1,3-butanedione l-oxime. The solution is poured into ice water and made basic with N sodium hydroxide. The solid which separates is collected and recrystallized from ethanol water to provide colorless prisms, melting point 8283 C.
EXAMPLE V Preparation of 3-methyl 4 (3 methyl 5 isoxazolyl) pyridine A solution of 13.2 g. (0.07 mole) of 4-acetoacetyl-3- methylpyridine, 5.9 g. of hydroxylamine hydrochloride, and 100 ml. of ethanol is heated under reflux for 18 hours, concentrated to a volume of ml., diluted with water, made basic with sodium carbonate, and extracted with 8 ether. The ether is evaporated and the residual oil is crystallized from pentane. Recrystallization from ether provides colorless crystals, melting point 8788 C.,
EXAMPLE VI Preparation of 4- S-methyl-B-isoxazolyl pyridine A solution of ml. of methyl acetylene, 400 ml. of ether, and 19.3 g. (0.10 mole) of isonicotinohydroxyamyl chloride hydrochloride is cooled to 40 C., and a solution of 28 ml. of triethylamine in ml. of ether is added dropwise with stirring during 2 hours. The mixture is stirred at -40 C. for 5 hours, and allowed to stand at room temperature for 20 hours. The mixture is diluted with water and sufiicient 1 N sodium hydroxide to achieve basicity, and is extracted with ether and chloroform. The organic extract is dried over anhydrous magnesium sulfate and concentrated to a solid. Recrystallization from hexane and sublimation at 100 C. (15 mm.) provides colorless needles, melting point 86-87 C.
EXAMPLE VII Preparation of 3-amino-1-(4-pyridyl)-2-buten-l-0ne A mixture of 20 g. (0.125 mole) of 4-(3-methyl-5- isoxazolyl)pyridine, 2.5 g. of platinum oxide, and 300 ml. of ethanol is hydrogenated at 40 p.s.i. for 3 hours. The mixture is filtered, and the filtrate is concentrated to a solid. Recrystallization from ethyl acetate provides colorless crystals, melting point 211213 C.
EXAMPLE VIII Preparation of 4-(3-methy1-5-isothiazolyl)pyridine A mixture of 3.6 g. (0.022 mole) of 3-amino-1-(4-pyridyIJ-Z-buten-l-one and 6 g. of phosphorus pentasulfide is fused at C. for 1 hour, cooled to room temperature, warmed with 1 N potassium hydroxide, and extracted with chloroform. The chloroform extract is dried over anhydrous magnesium sulfate and concentrated to a solid. Sublimation at 90 C. (18 mm.) provides colorless needles, melting point 56-60 C.
EXAMPLE 1X Preparation of 1-amino-1-(4-pyridyl)-1-buten-3-one A mixture of 0.48 g. (0.003 mole) of 4-(5-methyl-3- isoxazolyl)pyridine, 0.1 g. of platinum oxide, and 35 ml. of ethanol is hydrogenated at 1 atmosphere for 18 hours and filtered. The filtrate is concentrated to a solid. Recrystallization from ethyl acetate-hexane followed by sublimation at C. (13 min.) provides pale yellow crystals, melting point 152153 C.
EXAMPLE X Preparation of 4-(5-methyl-3-isothiazo1yl)pyridine A mixture of 1.0 g. (0.0062 mole) of 1-amino-1-(4- pyridyl)-1-buten-3-one and 1.8 g. of phosphorus pentasulfide is fused at for /2 hour, cooled, diluted with water, made alkaline with 1 N potassium hydroxide, and extracted with chloroform. The chloroform solution is dried over anhydrous magnesium sulfate and concentrated to a solid. Sublimation at 115 C. (15 mm.) provides colorless needles, melting point 49-52 C.
EXAMPLE XI Preparation of 1-methyl-4-(3-methyl-5-isoxazoly1)pyridinium chloride A mixture of 100 g. (0.62 mole) of 4-(3-methyl-S-isoxazolyl) pyridine and 350 ml. of methyl chloride is heated at 100 C. in a bomb for 15 hours. The excess methyl chloride is allowed to evaporate, and the residue is recrystallized from isopropyl alcohol to afford 56 g. (43%) of colorless crystals, melting point 248 C., dec.,
9 EXAMPLE XII Preparation of 1-methyl-4-(3-ethyl-5-isoxazolyl)pyridinium chloride A mixture of 8.7 g. (0.05 mole) of 4-(3-ethyl-5-isoxazolyl)pyridine and ml. of methyl chloride is heated at 95 C. in a bomb for 17 hours. The excess methyl chloride is allowed to evaporate, and the residue is recrystallized from isopropyl alcohol to give colorless crystals, melting point ZOO-201 C., dec.
EXAMPLE XIII Preparation of l allyl-4-(3-methyl-5-isoxazolyl)pyridinium chloride A mixture of 10.0 g. (0.052 mole) of 4-(3-methyl-5- isoxazolyl)pyridine and ml. of allyl chloride is heated at 80 C. in a bomb for IV: hours. The excess allyl chloride is decanted from a dark oil which is formed, and the oil is crystallized from acetonitrile to give 6.5 g. of tan crystals, melting point 7982 C. Recrystallization gives pale yellow needles, melting point 87 C., dec.
EXAMPLE XIV Preparation of l-n-propyl-4-(3-methyl 5 isoxazolyl) pyridinium bromide A mixture of 3.2 g. (0.02 mole) of 4-(3-methyl-5-isoxazolyl)pyridine and 10 ml. of n-propyl bromide is heated in a bomb at 100 C. for 20 hours. The solid which forms is collected, washed with ether, and recrystallized from isopropyl alcohol to provide colorless crystals, melting point 180-182 c.
EXAMPLE XV Preparation of 1-ethyl-4-(3-methyl-5-isoxazolyl) pyridinium iodide A solution of 3.20 g. (0.02 mole) of 4-(3-methyl-5- isoxazoyUpyridine, 4.5 g. of ethyl iodide, and ml. of ethanol is heated under reflux for 2 hours, and then concentrated to dryness. The residue is crystallized from isopropyl alcohol to provide yellow crystals, melting point 193-194 C., dec.
EXAMPLE XVI Preparation of l-cyclopropylmethyl-4-(3-methyl-5- isoxazolyDpyridiniurn bromide A solution of 3.20 g. (0.02 mole) of 4-(3-methyl-5 isoxazolyl)pyricline and 10 ml. of cyelopropylmethyl brornide is heated ona steam bath for 36 hour. Two layers form, and the lower layer is separated and recrystallized from acetonitrile to provide colorless crystals, melting point 165166 C., dec.
EXAMPLE XVII Preparation of l-( 2-methoxyethyl -4- 3-methyl-5- isoxazolyl pyridinium chloride A mixture of 3.2 g. (0.02 mole) of 4-(3-methyl-5- isoxazolyl)pyridine and 2 g. of 2methoxyethyl chloride is heated on a steam bath for 19 hours. The mixture is treated with ether and the insoluble tarry residue is stirred with acetone to provide 2.4 g. of tan solid, melting point 72-77 C. Recrystallization from isopropyl alcohol provides ofl-white crystals, melting point 73-74" C.,
iggg 293 my EXAMPLE XVIII Preparation of 1-methyl-4-(5-isoxazoyl)pyridinium chloride A mixture of 2.5 g. (0.017 mole) of 4-(5-isoxazolyl)- pyridine and 20 ml. of methyl chloride is heated at 900 C. in a bomb for 20 hours. The excess methyl chloride is allowed to evaporate and the solid residue is recrystallized from acetonitrile to provide 2.2 g. (65%) of colorless crystals, melting point 182-183 C., dec.
Preparation of l-ethyl-4-(3-ethyl-5-isoxazolyl)pyridinium iodide A solution of 3.5 g. (0.02 mole) of 4-(3-ethyl-5-isoxazolyl)pyridine, 4.5 g. of ethyl iodide, and 25 ml. of ethanol is heated under reflux for 2 hours, and then concentrated to an oil. Crystallization from isopropyl alcohol provides yellow crystals, melting point 154 C., dec.
EXAMPLE XXI Preparation of 1-rnethyl4-(5-trifiuoromethyl-3- isoxazolyl pyridinium chloride A mixture of 1.5 g. (0.007 mole) of 4-(5-trifl'uoromethyl-3-isoxazolyl) pyridine and 5 ml. of methyl chloride is heated in a bomb at 140 C. for 4 hours. The excess methyl chloride is allowed to evaporate, and the solid residue is recrystallized from isopropyl alcohol to provide colorless crystals, melting point 230 C., dec.
EXAMPLE XXII Preparation of 1,3-dimethyl-4-(3-methy1-5 -isoxazolyl) pyridinium chloride A mixture of 1.9 g. (0.011 mole) of 3-methyl-4-(3- methyl-S-isoxazolyl)pyridine and 20 ml. of methyl chloride is heated in a bomb at C. for 18 hours. The excess methyl chloride is allowed to evaporate, and the solid residue is recrystallized from acetonitrile to provide colorless crystals, melting point 246247 C., dec.
EXAMPLE XXIII Preparation of 1-n-propyl-4-(3-ethyl-5-isoxazolyl) pyridinium bromide A solution of 3.5 g. (0.02 mole) of 4-(3-ethyl-5-isoxazolyl)pyridine and 10 ml. of n-propyl bromide is heated at 100 C. in a bomb for 18 hours. The excess n-propyl bromide is decanted from a tar which forms, and the latter is triturated with acetone to provide colorless crystals. Recrystallization from isopropyl alcohol-ether gives colorless needles, melting point 153 C.
EXAMPLE XXIV Preparation of 1-methyl-4-acetoacetylpyridiniurn chloride A mixture of 5.0 g. (0.03 mole) of 4-acetoacetylpyri dine and 20 ml. of methyl chloride is heated at C. in a bomb for 15 hours. The excess methyl chloride is allowed to evaporate, and the solid residue is washed with ether, leaving 4.9 g. of tan crystals, melting point 192- 196 C. Recrystallization from isopropyl alcohol gives tan crystals, melting point 197-198 C., dec.
EXAMPLE XXV Preparation of 1-methyl-4-(5-methyl-3-isoxazolyl) pyridinium chloride A mixture of g. (0.47 mole) of l-methyI-4-aoei0- acetylpyridinium chloride, 35 g. of hydroxylamine hydrochloride, and 1.25 l. of ethanol is heated under reflux with stirring for 3 hours, stirred at room temperature for 18 hours and diluted with 2 l. of ether. The solid which separates is recrystallized from isopropyl alcohol-ether to provide 52 g. of colorless solid, melting point 100-l20 C., dec. This solid is a 1:1 mixture of 1-methyl-4-(3- methyl-S-isoxazolyl)pyridinium chloride and l-methyl-4- 1 l (i-methyl-ll-isoxazolyl)pyridinium chloride. The mixture is separated into two components by partition chromatography. The first eluted material is recrystallized from acetonitrile to provide colorless crystals, melting point 22l-222 C., dec., of 1-methyl-4-(5-methyl-3isoxazolyl) pyridinium chloride.
EXAMPLE XXVI Preparation of l-methyl-4-(3-rnethyl-5-isothiazolyl) pyridinium iodide A solution of 0.4 g. (0.0023 mole) of 4-(3-methyl-5- isothiazolyl)pyridine, 2 ml. of methyl iodide, and 15 ml. of ethanol is heated under reflux for 1.5 hours, cooled, and diluted with ether. A solid separates and is recrystallized from acetonitrile-ether to provide yellow crystals, melting point 176-177" C., dec.
EXAMPLE XXVII Preparation of 1-methyl-4-(5-methyl-3-isothiazolyl) pyridinium iodide A solution of 0.26 g. (0.0015 mole) of 4-(5-metl1yl-3- isothiazolyl)pyridine, 2 ml. of methyl iodide, and 100 ml. of ethanol is heated under reflux for 1.5 hours, cooled, and diluted with ether. A solid separates and is recrystallized from ethanol-ether to provide yellow crystals, melting point 110-1 12 C., dec.
EXAMPLE XXVllI Preparation of tablet compositions containing lmethyl- 4- 3-rnethyl-5 -isoxazolyl pyridinium chloride Per 1000 tablets, grams 1-methyl-4-(3-methyl 5 isoxazolyl)pyridinium chloride 10.0 Corn starch USP 30.0 Dibasic calcium phosphate 215.0 Magnesium stearate 6.0
The above ingredients are thoroughly mixed and incorporated into a standard pharmaceutical tablet. Each tablet contains mg. of active component.
EXAMPLE XXIX Preparation of hard shell capsules containing l-methyL 4-(5-isoxazolyl)pyridinium chloride Per 1000 capsules, grams l-methyl-4-(5-isoxazolyl)pyridinium chloride 20.0 Lactose 90.0 Magnesium stearate 1.0 The active component, lactose and magnesium stearate are blended together. The mixture is used to fill hard shell capsules of a suitable size each containing mg. of active component.
EXAMPLE XXX Preparation of oral syrup of l-methyl-4-(5-methyl-3- isoxazolyl pyridinium chloride Amt. per 100 ml. l-methyl 4 (5 methyl-3-isoxazolyl) Dissolve the sucrose and parabens in 40 ml. of purified water at 80 C. cool to C. and add and dissolve the sodium saccharin, sodium citrate, dye and flavor. Add and dissolve the pyridinium chloride. Adjust to final volume with purified water. Each teaspoonfull (4 ml.) contains 15 mg. of the active component.
We claim:
1. A method of lowering blood sugar levels in warmblooded animals which comprises administering to said animals a blood sugar lowering amount of a quaternary isoxazolylpyridinium salt of the formula:
wherein R is selected from the group consisting of hydrogen, lower alkyl, and trifiuoromethyl; R is selected from the group consisting of hydrogen and lower alkyl; R is selected from the group consisting of lower alkyl, lower alkenyl, cyclopropyl(lower)alkyl and lower alkoxyflower)alkyl; Z is a trivalent radical selected from the group consisting of and i t; :N O/
represents one double bond; X is a monovalent pharmaceutically acceptable anion and a pharmaceutical carrier.
2. The method according to claim 1, wherein the quaternary isoxazolylpyridiniurn salt is l-methyl-4-(3-methyl- S-isoxazolyl) pyridinium chloride.
3. The method according to claim 1, wherein the quaternary isoxazolylpyridinium salt is l-methyl-4-(3-e-t hyl-5- isoxazolyUpyridinium chloride.
4. The method according to claim 1, wherein the quaternary isoxazolylpyridiniurn salt is 1-allyl-4-(3-methyl-5- isoxazolyl) pyridinium chloride.
5. The method according to claim 1, wherein the quaternary isoxazolylpyridinium salt is 1-rnethyl-4-(5-methyl- 3-isoxazolyl)pyridinium chloride.
6. The method according to claim 1, wherein the quaternary isoxazolylpyridinium salt is 1,3-dimethyl-4-(3- methyl-S-isoxazolyl)pyridinium chloride.
7. The method according to claim 1, wherein the quaternary isoxazolylpyridinium salt is l-cyclopropylmethyl- 4-(3-rnethyl-5-isoxazolyl)pyridinium bromide.
8. An orally administerable composition for lowering blood sugar levels in warmblood animals which comprises a pharmaceutically acceptable carrier and from 1 mg. to 500 mg. per kilograms of warm-blooded animal body weight of a quaternary isoxazolylpyridinium salt of the formula:
consisting of represents one double bond and X is a monovalent pharmaceutically acceptable anion.
9. The composition according to claim 8, wherein the quaternary isoxazolylpyridinium salt is l-methyl-4-(3- methyl-S-isoxazolyl)pyridinium chloride.
I 0 and References Cited UNITED STATES PATENTS 2,929,819 3 1960 iErlewmeyer 260296 FOREIGN PATENTS 875,887 8/1961 Great Britain 260-296 JEROME D. GOLDBERG, Primary Examiner
US875528A 1966-03-21 1969-11-10 Compositions containing 4-(isoxazol-3 or 5-yl)-pyridinium salts and method of lowering blood sugar levels Expired - Lifetime US3592899A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US53571466A 1966-03-21 1966-03-21
US66228167A 1967-08-22 1967-08-22
US87552469A 1969-11-10 1969-11-10
US87552869A 1969-11-10 1969-11-10

Publications (1)

Publication Number Publication Date
US3592899A true US3592899A (en) 1971-07-13

Family

ID=27504658

Family Applications (3)

Application Number Title Priority Date Filing Date
US662281A Expired - Lifetime US3511848A (en) 1966-03-21 1967-08-22 Certain 4-(isoxazol-3 or 5-yl)-pyridinium salts
US875524A Expired - Lifetime US3598829A (en) 1966-03-21 1969-11-10 Certain isoxazolylpyridines and isothiazolylpyridines
US875528A Expired - Lifetime US3592899A (en) 1966-03-21 1969-11-10 Compositions containing 4-(isoxazol-3 or 5-yl)-pyridinium salts and method of lowering blood sugar levels

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US662281A Expired - Lifetime US3511848A (en) 1966-03-21 1967-08-22 Certain 4-(isoxazol-3 or 5-yl)-pyridinium salts
US875524A Expired - Lifetime US3598829A (en) 1966-03-21 1969-11-10 Certain isoxazolylpyridines and isothiazolylpyridines

Country Status (7)

Country Link
US (3) US3511848A (en)
BE (1) BE695882A (en)
CH (1) CH505137A (en)
DE (1) DE1645958A1 (en)
FR (1) FR7030M (en)
GB (1) GB1178604A (en)
NL (1) NL6704168A (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3678062A (en) * 1970-09-08 1972-07-18 American Cyanamid Co Certain 4-/(indazol-3-yl)-pyridinium/compounds
US3956343A (en) * 1975-04-04 1976-05-11 American Cyanamid Company Novel 5-vinyl-3-isoxazolyl substituted pyridines
US3966748A (en) * 1975-05-08 1976-06-29 American Cyanamid Company Para-fluorophenyl-N-heterocyclic substituted butanes
US3985754A (en) * 1975-05-08 1976-10-12 American Cyanamid Company Para-fluorobenzoylpropyl-N-heterocyclic substituted quaternary salts
US4346094A (en) * 1980-09-22 1982-08-24 Eli Lilly And Company 3-Aryl-5-isothiazolecarboxylic acids and related compounds used to lower uric acid levels
US6068648A (en) * 1998-01-26 2000-05-30 Orthodyne, Inc. Tissue anchoring system and method

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE569324A (en) * 1957-07-11
GB875887A (en) * 1959-01-21 1961-08-23 Ilford Ltd Improvements in or relating to direct positive emulsions

Also Published As

Publication number Publication date
BE695882A (en) 1967-09-21
US3511848A (en) 1970-05-12
NL6704168A (en) 1967-09-22
US3598829A (en) 1971-08-10
CH505137A (en) 1971-03-31
DE1645958A1 (en) 1970-06-04
GB1178604A (en) 1970-01-21
FR7030M (en) 1969-06-09

Similar Documents

Publication Publication Date Title
JPS6089474A (en) Morphinan derivative, production thereof and antitumor agent containing said compound
DE1695093A1 (en) New imidazole derivatives
DE2249644A1 (en) NEW ORGANIC COMPOUNDS AND PROCEDURES FOR THEIR PRODUCTION
DE2638184A1 (en) SUBSTITUTED PHENYL-PIPERAZINE-N-OXIDES, PROCESS FOR THEIR MANUFACTURING AND MEDICINAL PRODUCTS CONTAINING THEM
US3592899A (en) Compositions containing 4-(isoxazol-3 or 5-yl)-pyridinium salts and method of lowering blood sugar levels
JPS625912B2 (en)
DE2616481A1 (en) BIS-QUARTAERE PYRIDINIUM-2-ALDOXIM SALT AND THE PROCESS FOR THEIR PRODUCTION
US4302462A (en) 4(or 3)-(3,4-Dihydroxyphenyl)pyridines, their cardiotonic use and cardiotonic use of their methyl ethers
US4081449A (en) Heterocyclic esters of alkylphenyl benzopyranopyridines
UA121046C2 (en) Indole derivatives
US3574842A (en) Compositions of 4-(1,2,4-oxadiazole-3 or 5-yl)pyridinium salts and method of lowering blood sugar levels with same
US3736327A (en) Isoxazolopyridine ketone derivatives
JPS61100579A (en) Pyridine derivative
US3705157A (en) Azolylpyridazine compounds and quaternary salts thereof
US4187379A (en) 3-Aryloxy-2-pyridinecarbonitrile 1-oxide compounds
JPS61158980A (en) 8 alpha-acylaminoergolines, manufacture and medicinal composition
JPS5852270A (en) Substituted 2-amino-3,4-dihydropyridine derivative, manufacture and use as drug
SE438857B (en) SET TO MAKE CHROMON DERIVATIVES
US4451469A (en) Selected 6-alkyl-and 4,6-dialkyl-2(1H)-pyridinones as cardiotonics
US3949074A (en) Cardiotonic pharmaceutical compositions containing a cardiac glycoside and method of use
SE436885B (en) NEW QUARTER SALTS OF 3-AMINO-17A-AZA-D-HOMOANDROSTAN DERIVATIVES AND PROCEDURES FOR PRODUCING THEREOF
DE2461039A1 (en) Antiinflammatory, antithrombotic phenyl-ketone - oxime derivs - prepd. from corresp. ketone and hydroxylamine
JPH0525170A (en) Pyridone derivative, its production and antiulcerous agent containing the same
JPH01104053A (en) Substituted pyridines as dopamine-beta- hydroxylase inhibitor
US4031212A (en) 3β-(4-Oxo-.alpha.-L-rhamnosyl)-β-hydroxy-bufa-4,20,22-trienolide